N3-Methyluridine | 2140-69-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: N3-Methyluridine
• 英文别名: 1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-methylpyrimidine-2,4-dione
• CAS: 2140-69-4
• 化学式: C₁₀H₁₄N₂O₆
• 分子量: 258.23
• InChiKey: UTQUILVPBZEHTK-UHFFFAOYSA-N

物化性质

• 熔点：
  108-110 °C
• 沸点：
  501.1±60.0 °C(Predicted)
• 密度：
  1.605±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO（微溶加热）、甲醇（微溶加热）、水（微溶超声处理）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8℃

制备方法与用途

生物活性

3-甲基尿苷（N3-甲基尿苷）是一种修饰的细胞RNA核苷。它通常以RNA修饰的形式出现，能够在古菌的23S rRNA、真细菌的16S和23S rRNA以及真核核糖体的18S、25S和28SrRNA中被检测到。

靶点

• 人内源性代谢物

反应信息

• 作为产物：
  描述：

  三甲基苯基氢氧化铵 、 尿嘧啶核苷 、 四甲基氢氧化铵 以3%的产率得到
  参考文献：
  名称：

  YAMAUCHI KIYOSHI; NAKAMURA KAZUE; KINOSHITA MASAYOSHI, TETRAHEDRON LETT., 1979, NO 20, 1787-1790

  摘要：

  DOI：

文献信息

• MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION
  申请人：Universität Basel

  公开号：EP3889602A1

  公开（公告）日：2021-10-06

  The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a eukaryotic cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.

  本发明涉及一种调节MR1多肽与MR1特异性T细胞受体分子之间相互作用的方法，其中MR1多肽与MR1配体化合物接触，MR1配体化合物是反映真核细胞代谢窘迫状态的核碱基加合物产物。 本发明进一步涉及鉴定为 MR1 配体的化合物在疫苗接种或调节 MR1 限制性免疫反应中的用途。
• Profiling chemically modified DNA/RNA units for disease and cancer diagnosis
  申请人：The Research Foundation for The State University of New York

  公开号：US11339441B2

  公开（公告）日：2022-05-24

  The present invention relates to high-throughput methods comprising direct infusion electrospray ionization mass spectrometry (ESI-MS), multistep tandem mass spectrometry (MSn), consecutive reaction monitoring (CRM), ion mobility spectrometry mass spectrometry (IMS-MS), high-resolution MS, and IMS-MS, for genome-wide (whole cell or tissue) profiling of DNA and RNA nucleotides/nucleosides having a wide variety of variant structural modifications. In particular, these methods are contemplated for providing a specific profile of variant DNA and/or RNA chemically modified nucleic acids (i.e. structures) associated with specific medical conditions. Medical conditions may include, but are not limited to: cancer; including prostate, lung, uterus, larynx, ovary, breast, kidney, and many other types of cancers; specific stages of cancer; bacterial infections; viral infections; genetic and metabolic disorders; and any condition involving changes in DNA and/or RNA structural modifications.

  本发明涉及高通量方法，包括直接注入电喷雾离子化质谱（ESI-MS）、多步串联质谱（MSn）、连续反应监测（CRM）、离子迁移谱质谱（IMS-MS）、高分辨率 MS 和 IMS-MS，用于对具有多种变异结构修饰的 DNA 和 RNA 核苷酸/核苷进行全基因组（全细胞或组织）分析。特别是，这些方法可用于提供与特定病症相关的变异 DNA 和/或 RNA 化学修饰核酸（即结构）的特定概况。病症可包括但不限于：癌症；包括前列腺癌、肺癌、子宫癌、喉癌、卵巢癌、乳腺癌、肾癌和许多其他类型的癌症；癌症的特定阶段；细菌感染；病毒感染；遗传和代谢紊乱；以及任何涉及 DNA 和/或 RNA 结构修饰变化的病症。
• PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS
  申请人：THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

  公开号：US20170044619A1

  公开（公告）日：2017-02-16

  The present invention relates to high-throughput methods comprising direct infusion electrospray ionization mass spectrometry (ESI-MS), multistep tandem mass spectrometry (MS n ), consecutive reaction monitoring (CRM), ion mobility spectrometry mass spectrometry (IMS-MS), high-resolution MS, and IMS-MS, for genome-wide (whole cell or tissue) profiling of DNA and RNA nucleotides/nucleosides having a wide variety of variant structural modifications. In particular, these methods are contemplated for providing a specific profile of variant DNA and/or RNA chemically modified nucleic acids (i.e. structures) associated with specific medical conditions. Medical conditions may include, but are not limited to: cancer; including prostate, lung, uterus, larynx, ovary, breast, kidney, and many other types of cancers; specific stages of cancer; bacterial infections; viral infections; genetic and metabolic disorders; and any condition involving changes in DNA and/or RNA structural modifications.
• [EN] MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION<br/>[FR] LIGANDS MR1 ET COMPOSITIONS PHARMACEUTIQUES POUR IMMUNOMODULATION
  申请人：UNIV BASEL

  公开号：WO2021144475A1

  公开（公告）日：2021-07-22

  The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.
• YAMAUCHI KIYOSHI; NAKAMURA KAZUE; KINOSHITA MASAYOSHI, TETRAHEDRON LETT., 1979, NO 20, 1787-1790
  作者：YAMAUCHI KIYOSHI、 NAKAMURA KAZUE、 KINOSHITA MASAYOSHI

  DOI：——

  日期：——